Safety and Efficacy of Jaktinib in the Treatment of Janus Kinase Inhibitor‐naïve Patients with Myelofibrosis: Results of a Phase II Trial
Yi Zhang,Hu Zhou,Zhongxing Jiang,Dengshu Wu,Junling Zhuang,Wei Li,Qian Jiang,Xiuli Wang,Jinwen Huang,Huanling Zhu,Linhua Yang,Xin Du,Fei Li,Ruixiang Xia,Feng Zhang,Jianda Hu,Yan Li,Yu Hu,Jing Liu,Chenghao Jin,Kai Sun,Zeping Zhou,Liqing Wu,Wenjuan Yu,Jie Jin
DOI: https://doi.org/10.1002/ajh.26709
IF: 13.265
2022-01-01
American Journal of Hematology
Abstract:Myelofibrosis (MF) is associated with several constitutional symptoms. Currently, there are few therapeutic options for MF. Jaktinib, a novel, small-molecule inhibitor of JAK, is currently being studied for its potential to treat MF. This phase 2 trial investigated efficacy and safety of jaktinib in the treatment of MF patients. The primary end point was the proportion of patients with >= 35% reduction in spleen volume (SVR35, proportion of patients with >= 35% reduction in spleen volume) at week 24. The secondary end points included improvement of anemia, rates of symptom response, and safety profile. Between January 8, 2019 and August 29, 2020, 118 patients were recruited and treated with either jaktinib 100 mg BID or 200 mg QD. At week 24, 54.8% (34/62) of patients in the 100 mg BID group and 31.3% (15/48) in the 200 mg QD group achieved SVR35 (p = .0199). Jaktinib treatment increased hemoglobin level to >= 20 g/L in 35.6% (21/59) of patients with hemoglobin <= 100 g/L at baseline. The proportion of patients who achieved a >= 50% improvement in total symptom score at week 24 was 69.6% (39/56) in the BID group and 57.5% (23/40) in the QD group. The most common >= grade 3 hematological treatment-emergent adverse events (TEAEs; >= 10%) were anemia (100 mg BID: 24.2%, 200 mg QD: 28.8%), thrombocytopenia (16.7%, 11.5%), and neutropenia (3.0%, 11.5%). All non-hematological TEAEs were mild. These results indicate that jaktinib can shrink the spleen, improve anemia, and other clinical symptoms with good tolerability.